Table 4.

Incidence of VTE in current users versus non-users of strontium ranelate or alendronate sodium

	Treated osteoporotic patients
	Strontium ranelate (N = 2,408)		Alendronate sodium (N = 20,084)
	Non-users	Current users	Non-users	Current users
Patients with VTE (N)	34	13	230	140
Annual incidence (per 1,000 PY)	6.8	7.0	6.2	7.2
HR (SE)a	0.90 (0.34)		0.99 (0.11)
95% CI	0.46–1.75		0.80–1.23
p value	0.75		0.96

During treatment exposure, patients belong to the cohort of current users; outside this period, they are considered as non-users

VTE venous thromboembolism (including deep venous thrombosis, pulmonary embolism, or retinal vein thrombosis), CI confidence interval, HR hazard ratio, SE standard error, PY patients–years

^aHR between groups based on a Cox proportional hazards model adjusted on age and with group included in a time-dependent fashion